Compare Quest Diagnostics Inc (DGX) vs Consumer Discretionary Select Sector SPDR Fund (XLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Consumer Discretionary Select Sector SPDR Fund — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while Consumer Discretionary Select Sector SPDR Fund trades at $112.85 (market cap $21.89B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Consumer Discretionary Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Consumer Discretionary Select Sector SPDR Fund for 114 Days on average.
| DGX | XLY | |
|---|---|---|
Market Cap | $25.48B | $21.89B |
Volume | 941,866 | 5,690,342 |
Sector | Health | — |
52-Week High | $247.45 | $124.52 |
52-Week Low | $173.49 | $105.64 |
Typical Hold Time | 56 Days | 114 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.97, up 1.75% today, with a technical bias leaning bearish despite recent earnings beats. Revenue grew to $11.04B in 2025, with net income reaching $992M, though profit margins have moderated. Analyst consensus is a $250 price target with a mixed buy/hold sentiment. Recent news highlights growth in consumer testing and partnerships, alongside concerns over potential Medicare reimbursement cuts.
The outlook balances solid fundamentals and growth initiatives against regulatory risks. Upside potential exists from continued operational execution and new ventures like the Apple Health app integration, but investors face headwinds from reimbursement uncertainty and a high debt load. The stock's valuation appears reasonable relative to peers, supporting a cautious but opportunistic view.
XLY trades at $112.85, up 1.34% with a bullish technical signal despite mixed momentum indicators. The ETF shows strong analyst consensus with 100% buy ratings but faces fundamental data gaps. Recent news highlights consumer discretionary sector challenges, with XLY underperforming staples by 13% year-to-date amid inflation pressures and selective consumer spending trends.
Outlook remains cautiously optimistic given analyst support, but persistent underperformance versus the S&P 500 and inflation risks warrant monitoring. The 'funflation' trend and potential holiday sales growth offer upside catalysts, though sector volatility and Tesla's weighting drag present near-term headwinds for discretionary exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Consumer Discretionary Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: retail; hotels, restaurants and leisure; textiles, apparel and luxury goods; household durables; automobiles; auto components; distributors; leisure products; and diversified consumer services. It is non-diversified.
Read more on XLY →
